Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174394 | 0.77 | TP53 (0.43) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL5972869 | 0.74 | CES2 (0.35) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL24311836 | 0.74 | CES2 (0.35) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL9728068 | 0.71 | CYP2C19 (0.47) | L3MBTL1ALDH1A1 | |
| SCHEMBL10130574 | 0.70 | KDM4E (0.43) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL10387818 | 0.67 | KDM4E (0.41) | KDM4ETDP1ALDH1A1 | |
| SCHEMBL5147000 | 0.67 | KDM4E (0.41) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL6641492 | 0.67 | KDM4E (0.41) | KDM4ETDP1ALDH1A1 | |
| SCHEMBL14340880 | 0.67 | L3MBTL1 (0.40) | KDM4ETDP1L3MBTL1CES2CES1 | |
| SCHEMBL13049960 | 0.66 | KDM4E (0.45) | KDM4ETDP1L3MBTL1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KDM4E 4122/4885TDP1 2985/4885L3MBTL1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.